Efficacious Cefazolin Prophylactic Dose for Morbidly Obese Women Undergoing Bariatric Surgery Based on Evidence from Subcutaneous Microdialysis and Populational Pharmacokinetic Modeling

Pharm Res. 2018 Apr 11;35(6):116. doi: 10.1007/s11095-018-2394-5.

Abstract

Purpose: To determine the efficacious cefazolin prophylactic dose for bariatric surgery using free subcutaneous concentrations accessed by microdialysis after 2 g or 3 g i.v. bolus dosing to morbidly obese women and POPPK modeling.

Methods: A POPPK model with variable plasma and subcutaneous tissue protein binding was developed to simultaneously describe plasma and tissue data sets. The outcomes was predicted for common surgical site infection (SSI) bacteria over 3, 4, 5 and 6 h periods postdose, as probability of target attainment (PTA) using Monte Carlo simulation.

Results: CFZ 2 g warrant up to 5 h SSI prophylaxis for bacteria with MICs ≤1 mg/L such as Escherichia coli and Staphylococcus aureus. For species such as Klebsiella pneumoniae, which present MIC distribution frequency of 2 mg/L, the maintenance of PTA ≥ 90% occurs with a 3 g dose for surgeries lasting up to 5 h, and 2 g dose provide an adequate response up to 4 h (PTA of 89%).

Conclusions: Effectiveness of CFZ 2 g is similar to 3 g against bacteria with a MIC up to 2 mg/L, especially if the surgery does not last for more than 4 h.

Keywords: cefazolin; microdialysis; morbid obesity; populational pharmacokinetics; β-lactam.

MeSH terms

  • Adult
  • Antibiotic Prophylaxis / methods*
  • Bariatric Surgery / adverse effects*
  • Bariatric Surgery / methods
  • Cefazolin / administration & dosage*
  • Cefazolin / pharmacokinetics
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Microbial Sensitivity Tests
  • Microdialysis
  • Middle Aged
  • Models, Biological*
  • Obesity, Morbid / surgery
  • Subcutaneous Tissue / metabolism
  • Surgical Wound Infection / etiology
  • Surgical Wound Infection / microbiology
  • Surgical Wound Infection / prevention & control*
  • Young Adult

Substances

  • Cefazolin